NCT04159662Recruiting
Brain Imaging of Cognition Inn Schizophrenia and Depression
Source: ClinicalTrials.gov · Last updated 23 Mar 2026
Brief summary (registry, in English)
Schizophrenia and depression are among the most disabling disorders in all of medicine. Cognitive deficits play a key role in patients' disability, affecting their capacity to contribute actively to society by sustaining employment or academic activity. Moreover, cognitive difficulties tend to persist even after the stabilization of other clinical symptoms. Verbal memory and emotion regulation are two important cognitive domains that are impaired in schizophrenia and depression and are associated with patients' functional outcomes. In this study, brain imaging is used to investigate the brain mechanisms underlying these cognitive deficits in these populations.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 90 (estimated)
- First submitted
- 25 Oct 2019
- Start date
- 12 Dec 2019
- Primary completion date
- 1 Oct 2026
- Lead sponsor
- The Royal Ottawa Mental Health Centre
- Diseases
- Schizophrenia, Depression
- NCT number
- NCT04159662
What you commit to
- Study type: Observational
- Planned participants: 90
- From 12 Dec 2019 to the primary completion date, 1 Oct 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- taking medications that are rated as Anticholinergic Burden (ACB) Score 3 (severe) or taking benzodiazepines on a daily basis
Other illness
- significant neurological or other medical disorders that may produce cognitive impairment
- a recent history of substance abuse or dependence (within the past 3 months)
- any magnetic resonance imaging (MRI) contraindications (e.g. metallic head implant, history of seizure, pacemaker)
- Finally, participants could not be severely symptomatic at the time of study enrolment to ensure that they could understand and complete all study assessments. This criterion was defined as a score ≤34 on the Montgomery-Åsberg Depression Rating Scale (MADRS; Montgomery \& Åsberg, 1979) for the MDD group and a score ≤95 on the Positive and Negative Syndrome Scale (PANSS; Kay et al., 1987) for the SZ group.
Other
- decisional incapacity requiring a guardian
Who the study is looking for
- age 18-60 years
- current Intelligence Quotient (IQ) \> 70 as measured by the Wechsler Abbreviated Scale of Intelligence (WASI)
- the ability to read and speak fluent English
- a diagnosis of schizophrenia, schizoaffective or major depression disorder
- stable medication for more than one month
Age in the registry: 18 years to 60 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Royal Ottawa Mental Health Center Coordinator of this site? Confirm its status | Ottawa | Canada | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.